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Abstract
Objective: The imbalance between neurotoxic cytokine tumor necrosis factor-_ (TNF-_) and neuro-
trophic cytokines epidermal growth factor (EGF) and interleukin-6 (IL-6) plays a role in the pathogen-
esis of cobalamin (Cbl) deficiency-induced neuropathy. The aim of this study was to evaluate auto-
nomic nervous system dysfunction and to look for any relationship between autonomic nervous system 
disturbances and serum cytokine levels (TNF-_, EGF, IL-6) in patients with Cbl deficiency.
Materials and Methods: Serum levels of TNF-_, EGF and IL-6 were studied in patients with Cbl defi-
ciency (n=41) and a healthy control group (n=17) and after 3 months in patients who underwent Cbl 
replacement therapy (n=22). All patients with Cbl deficiency underwent electrophysiological studies 
(EPS) for the diagnosis of neuropathy. Statistical analysis was performed using SPSS for Windows 
11.5 software.
Results: With EPS, 29 of 41 Cbl-deficient patients (70.73%) demonstrated neurological dysfunction 
[3 (7.32%), 19 (46.34%) and 7 (17.07%) patients with sensorimotor peripheral neuropathy, parasym-
pathetic, and sympathetic autonomic dysfunction, respectively]. Although there was no significant 
difference in serum levels of EGF and IL-6 between patients with versus without autonomic dysfunc-
tion, levels were significantly lower in Cbl- deficient patients than healthy controls.
Conclusion: Presence of autonomic dysfunction seems to be a frequent neurological finding in patients 
with Cbl deficiency. However, we could not find any relationship between serum cytokine levels and 
autonomic dysfunction by EPS. (Turk J Hematol 2010; 27: 250-6)
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The clinical presentation of patients with vitamin 
B12 (cobalamin-Cbl) deficiency varies in a spectrum 
ranging from hematological disorders to neuropsy-
chiatric diseases. As the level of Cbl deficiency does 
not correlate with the severity of neurological disor-
ders and the lesions may become irreversible if not 
treated promptly, neurological abnormalities are a 
matter of clinical concern in patients with Cbl defi-
ciency. Cbl deficiency may affect both the periph-
eral and central nervous system, with diminished 
vibratory sensation as the most common abnormal-
ity [1,2]. In rare cases, autonomic nervous system 
dysfunction presented as orthostatic hypotension, 
impotence, constipation, and urinary retention have 
been attributed to Cbl deficiency [1,3,4]. Although 
the association between Cbl deficiency and neuro-
logical abnormalities is well known, the precise 
mechanism by which neurological impairment 
occurs is not yet obvious [5]. Neurological abnor-
malities may occur not only in patients with classic 
Cbl deficiency but also in subtle or atypical deficien-
cies in which anemia is absent [6]. In previous 
reports, the pathogenesis of neurological abnor-
malities due to Cbl deficiency has been attributed to 
the accumulation of methylmalonic acid (MMA) 
and homocysteine (Hcys). However, in totally gas-
trectomized Cbl-deficient rat models, Scalabrino et 
al. [7-9] showed that the severity of the neuropatho-
logical damage in the spinal cord white matter did 
not correlate with the progressive accumulation of 
MMA and Hcys, and it was suggested that some 
cytokines and/or growth factors other than MMA 
and Hcys might play a role in the pathogenesis of 
neurological damage in Cbl deficiency. Experimental 
studies over the last few years have demonstrated 
that Cbl deficiency increases the local overexpres-
sion of neurotoxic cytokine tumor necrosis factor-_ 
(TNF-_) and decreases the synthesis of the neuro-
trophic epidermal growth factor (EGF) and interleu-
kin-6 (IL-6) in the cerebrospinal fluid (CSF) of rats 
[10-12]. On the basis of these experimental obser-
vations, we measured the serum levels of TNF-_, 
EGF and IL-6 in adult patients with Cbl deficiency 
and investigated the effect of these factors on neu-
rological abnormalities, especially on autonomic 
dysfunction as assessed by electrophysiological 
studies (EPS). We also investigated the effect of 
replacement therapy with Cbl in some of these 
patients. 
Materials and Methods
Subjects
The study population consisted of newly diag-
nosed and untreated patients with Cbl deficiency 
(n=41), healthy volunteers as a control group 
(n=17) and patients after three months of treatment 
for Cbl deficiency (n=22). 
Özet
Amaç: Nörotoksik sitokin tumor necrosis factor-_ (TNF_) ile nörotrop sitokinler epidermal growth 
factor (EGF) ve interleukin-6 (IL-6) aras×ndaki dengesizlik kobalamin eksikliùine baùl× nöropati pato-
jenezinde rol oynamaktad×r. Bu çal×üman×n amac×, kobalamin eksikliùi olan hastalarda otonom sinir 
sistemi bozukluùunu deùerlendirmek ve otonom sinir sistemi bozukluklar× ile serum sitokin düzeyleri 
(TNF_, EGF, IL-6) aras×ndaki iliükiyi araüt×rmakt×r.
Yöntem ve Gereçler: Kobalamin eksikliùi olan hastalar (n=41), saùl×kl× kontrol grubu (n=17) ve 
kobalamin yerine koyma tedavisinden 3 ay sonra hastalarda (n=22) serum TNF_, EGF, IL-6 düzeyleri 
çal×ü×ld×. Nöropati tan×s× için, Cbl eksikliùi olan tüm hastalarda elektrofizyolojik çal×üma (EPS) yap×ld×. 
ústatistik analizde “SPSS for Windows 11.5” yaz×l×m× kullan×ld×.
Bulgular: EPS ile 41 kobalamin eksikliùi olan hastadan 29’unda nörolojik bozukluk gösterildi [ 3 
(7.32%), 19 (46.34%) ve 7 (17.07%) hastada s×ras×yla, sensorimotor periferal nöropati, parasempatik 
ve sempatik otonom bozukluk]. Otonom bozukluk olan ve olmayan hastalar aras×nda serum EGF ve 
IL-6 düzeylerinde anlaml× fark yoksa da, bu sitokin düzeyleri kobalamin eksikliùi olan hastalarda, 
saùl×kl× kontrolerden anlaml× derecede düüüktü.
Sonuç: Kobalamin eksikliùi olan hastalarda otonom bozukluk, s×k nörolojik bulgu olarak görünmekte-
dir. Bununla birlikte, elektrofizyolojik çal×ümayla saptanan otonom bozukluklar ve serum sitokin 
düzeyleri aras×nda iliüki bulamad×k. (Turk J Hematol 2010; 27: 250-6)
Anahtar kelimeler: Kobalamin eksikliùi, otonom bozukluk, disotonomi, otonom nöropati, serum 
sitokin düzeyi
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The diagnosis of Cbl deficiency was based on the 
finding of low serum Cbl with normal serum folate 
levels and high plasma levels of Hcys. Cut-off value 
of serum Cbl was accepted as 160 pmol/L. 
The patients with Cbl deficiency aged 16-80 years 
who had none of the exclusion criteria were enrolled 
into the study. Patients with a history of diabetes 
mellitus, uremia, chronic hepatitis, concomitant 
malignancies, alcohol abuse, drug use, folate defi-
ciency, or other possible causes of polyneuropathy 
were excluded. None of the patients had apparent 
infection or any generalized/localized infection sign 
such as fever, leukocytosis or erythema, and none 
of them had malabsorption, were following a vege-
tarian diet, or had previous gastric surgery.
All the patients underwent careful medical his-
tory and physical and neurological examination. As 
a part of the medical history, all patients were que-
ried regarding the presence of autonomic dysfunc-
tion symptoms such as orthostatic hypotension, 
impotence, constipation, diarrhea, and inconti-
nence. Routine blood chemistry tests, complete 
blood cell count and measurements of Hcys levels, 
serum Cbl levels and folate concentrations were 
performed. Serum MMA levels could not be mea-
sured due to technical limitations in our hospital. 
Serum levels of TNF-_, EGF and IL-6 were studied in 
patients with Cbl deficiency, the healthy control 
group and after 3 months of Cbl replacement. All 
patients with Cbl deficiency underwent EPS for the 
diagnosis of neuropathy. Anti-parietal cell antibody 
(APA) test, gastroduodenoscopy and endoscopic 
biopsies were also performed in patients with Cbl 
deficiency.
Control group
Healthy volunteers, who served as normal con-
trols, were defined following a detailed clinical his-
tory and physical examination, with normal base-
line blood tests including full blood count, fasting 
glucose, renal function, hepatic function, electro-
lytes, and serum Cbl. They had no acute or chronic 
disease such as diabetes mellitus, infections, rheu-
matologic disorders, immune dysfunctions, or any 
neurological disorders. 
Cobalamin replacement therapy group 
After tests had been completed, intramuscular 
Cbl injections were started for patients with Cbl 
deficiency. Cobalamin was given at a dose of 1000 
g per day with intramuscular injection (week 1), 
1000 g twice weekly (week 2), 1000 g/week for 
the third and fourth weeks, and then 1000 g/
month. Three months after the initiation of therapy, 
available patients were reevaluated for the pres-
ence of neurological findings and serum cytokine 
levels.
All participants gave informed consent prior to 
participation in the study, and the study was 
approved by the local Ethics Committee. 
Methods
Peripheral venous blood samples of 2 ml and 8 
ml were drawn after an overnight fast without stasis 
from an antecubital vein with a 21-gauge needle 
into ethylene diamine tetra-acetic acid (EDTA)-
containing tubes and empty tubes, respectively. 
Serum samples were separated within 1-3 hours 
and stored at -80°C until assayed. Serum Cbl, folate 
and plasma Hcys concentrations were measured 
using commercial kits. 
Serum Cbl assay was performed by chemilumi-
nescence method using commercial kits on the 
ADVIA Centaur chemistry analyzer (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA).
Serum TNF-_, EGF and IL-6 assays were mea-
sured by means of an enzyme immunoassay kit 
(Biosource human TNF-_ ultrasensitive ELISA, 
human EGF ELISA and human IL-6 ultrasensitive 
ELISA kit, Biosource International Inc., Camarillo, 
CA, USA).
Electrophysiological study (EPS) 
Electrophysiological studies (EPSs) carried out in 
all the patients with Cbl deficiency included motor 
and sensory nerve conduction studies, RR interval 
variation (RRIV) and sympathetic skin response 
(SSR). 
Patients underwent motor and sensory nerve 
conduction studies of the right median, peroneal 
and sural nerves. Motor studies included wrist-
elbow and knee-ankle segments of the median and 
peroneal nerves, respectively. Sensory nerve con-
duction was performed orthodromically on the digit 
II-wrist segment of the median nerve. The sural 
nerve was stimulated at midcalf, and recordings 
were made antidromically just lateral and posterior 
to the lateral malleolus. Stimuli were delivered 
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Whenever nerve conduction abnormalities were 
found in the studied nerves, other motor and sen-
sory nerves in the upper or lower extremities were 
also studied to rule out mono- or polyneuropathies. 
Recordings were performed by surface electrodes.
RRIV was studied by a Dantec Cantata electro-
myograph as described previously [13]. Recordings 
were made by using silver-silver chloride electrodes 
with a 7x4 mm recording area placed on the dorsum 
of each hand. Bandpass filters were set at 20-100 Hz 
and the sensitivity was 200-500 V per division. 
Oscilloscope was triggered at a sweep of 200 ms per 
division, which permitted display of 2 QRS complex-
es on the screen. Latency variations of the second 
complex were measured in each sweep. Five groups 
of 20 tracings were recorded at rest and two during 
deep breathing. The range of RR intervals (a) and the 
mean RR interval (b) were measured, and RRIV was 
calculated according to the following formula: a/
bx100. The averages of five recordings at rest and 
two recordings during deep breathing were termed 
R% and D%, respectively. D%-R% and D%/R% were 
also calculated and compared to normative data of 
Shahani et al. [13]. Values lower than the 95% confi-
dence limits in any of the four calculated variables 
were considered abnormal [parasympathetic (car-
diovagal) dysfunction]. 
SSR was recorded from both hands and feet 
using the same equipment and electrodes described 
in RRIV testing. The cathode was attached either to 
palms or soles, referenced as the dorsum of the 
hand or foot. Bandpass filters were set at 0.5-2000 
Hz. Sensitivity was 500 V per division, with a sweep 
of 500 ms per division for upper extremity and 1 s 
per division for lower extremity recording. Responses 
were elicited by delivering electrical stimuli to the 
contralateral median or tibial nerves. At least four 
tracings were obtained from each site. Abnormality, 
sympathetic (sudomotor) dysfunction, was defined 
as absence of any response in these recordings. 
Statistical analysis
Statistical analysis was performed using SPSS for 
Windows 11.5 software. Student’s paired-t test and 
Wilcoxon ranks test were used for within-group 
comparison. Mann-Whitney U test was used for 
comparisons between groups. The relationships 
between the variables were assessed using either 
Spearman’s or Pearson correlation tests. Data for 
TNF-_ and IL-6 levels are expressed as 
median±standard deviation (SD). Data for EGF lev-
els are expressed as mean±SD. Differences were 
considered significant if p<0.05.
Results
A total of 41 consecutive patients with newly 
diagnosed and untreated Cbl deficiency (17 male, 
24 female, age range: 19-75 years, median: 43 years) 
were included. Twenty-two of the 41 patients were 
re-evaluated after three months of parenteral Cbl 
replacement treatment. The control group consist-
ed of 17 healthy volunteers (11 female, 6 male, age 
range: 16-70 years, median: 42 years).
Initial presenting symptoms and signs of the 
patients were: fatigue in 16/41 (39%), neurological 
symptoms including paresthesias, dizziness, ataxia, 
memory loss, and syncope in 31/41 (75.6%), anemia 
and/or macrocytosis in 19/41 (46.34%), and gastro-
intestinal symptoms in 3/41 (7.3%). Tingling (pins 
and needles) and/or numbness in hands and/or 
feet, evaluated as paresthesias, were present in 
12/41 patients (29.26%). Neurological examination 
showed positive Romberg’s sign in 15/41 patients 
(36.58%), extensive vibratory sense loss in 13/41 
patients (31.70%), and decreased deep tendon 
reflex in 5/41 patients (12.19%).
Upper gastrointestinal system endoscopic exam-
ination was performed in 30/41 patients. 16/30 
patients (53.3%) had Helicobacter pylori infection. 
Nine of 30 patients (30%) had atrophic gastritis. In 5 
of 9 patients with atrophic gastritis (55.5%), APAs 
were positive. 
Eleven (26.80%) patients had macrocytic anemia 
and in 4 of these patients, leukopenia and/or throm-
bocytopenia was also present. In 9 of 41 patients 
(21.95%), additional iron deficiency was present. 
Hematological variables in patients with Cbl defi-
ciency were as follows: hemoglobin 11,33±2,48 g/
dl, mean corpuscular volume (MCV) 91,85±17,19 fl, 
leukocyte 5.85±1.65 x109/L, and platelet count   
240.20±93.84 x109/L Median value of serum Cbl lev-
els was 114,83±39,82 pmol/L. Median serum levels 
of TNF-_ and IL-6 were 0,17±0,27 pg/ml (range: 
0,13-1,9) and 0,09±0,21 pg/ml (range: 0,08 - 1,47), 
respectively. Mean serum level of EGF was 1,15±0,73 
pg/ml (range: 0,06 - 2,68). Hematological variables, 
serum Cbl levels, and serum IL-6, TNF-_ and EGF 
levels in Cbl-deficient patients and in healthy con-
trols are summarized in Table 1. 
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lower in patients with Cbl deficiency than healthy 
controls [1.15±0.73 vs 1.96±0.93 (p=0.001) and 
0.09±0.21 vs 0.13±0.84 (p=0.006), respectively]. 
Serum TNF-_ levels were not significantly different 
between Cbl-deficient patients and healthy controls 
[median 0.17±0.27 (range: 0.13 - 1.9) vs 0.18±0.97 
(range: 0.15 - 3.12) pg/ml, p>0.05]. Serum TNF-_ 
and IL-6 levels were not significantly different 
between Cbl-deficient patients and after Cbl 
replacement treatment [median 0.17±0.27 (range: 
0.13 - 1.9) vs 0.19±0.17 (range: 0.07 - 1.47) pg/ml, 
and 0.09±0.21 (range 0.07 - 1.47) vs 0.09±0.08 
(range 0.04 - 0.45) pg/ml, respectively, p>0.05]. 
However, serum EGF levels significantly increased 
after Cbl replacement treatment (1.13±0.73 vs 
1.90±0.74, p=0.005). Serum levels of TNF-_, IL-6 
and EGF did not correlate with any of the consid-
ered hematological variables in patients with Cbl 
deficiency or in controls. Serum Cbl, IL-6, TNF-_, 
and EGF levels were not significantly different in 
Cbl-deficient patients with autonomic neuropathy 
than in patients without neuropathy (p>0.05). 
Serum levels of IL-6, EGF and TNF-_ were not sig-
nificantly different between patients whose auto-
nomic neuropathy findings responded versus did 
not respond to Cbl replacement treatment (p>0.05). 
According to the EPS, 12/41 patients (29.27%) 
had normal EPS findings, while 29/41 patients 
(70.73%) demonstrated neurological abnormalities. 
Sensorimotor peripheral neuropathy and autonom-
ic dysfunction according to EPS were present in 
3/41 patients (7.32%) and 26/41 patients (63.41%), 
respectively. In detail, autonomic dysfunction by 
EPS was parasympathetic (cardiovagal) dysfunction 
in 19 patients (46.34%) and sympathetic (sudomo-
tor) dysfunction in 7 (17.07%) (Figure 1). Twenty-
two of 41 patients were re-evaluated with hemato-
logical variables, neurological examination and 
serum cytokine levels after three months of paren-
teral Cbl replacement treatment. After Cbl replace-
ment, a follow-up EPS could be evaluated in 13 
patients with neuropathy, and improvement was 
achieved in only 5 patients (38.46%).
Discussion
In our study, we demonstrated that serum EGF 
and IL-6 levels were significantly decreased in 
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Table 1. Hematological variables, serum cobalamin and cytokines levels of study groups
    Patients with  Healthy controls  p Value
   Cbl  deficiency  (n=17) 
   (n=41)
Hematological variables (mean values)
 WBC  (x109/L)   5.85±1.65  6.99±1.70  p>0.05
 Hemoglobin  (g/dl)  11.33±2.48  13.19±1.62  p<0.05
  Mean corpuscular volume (fl)  91.85±17.19  84.79±9.37  p>0.05
 Platelets  (x109/L) 240.20±93.84    274.90±39.15  p>0.05
Serum cobalamine level (pmol/L) mean   114.83±39.82  217.00±48.18  p<0.001
Serum IL-6 level (pg/ml) median  0.09±0.21   0.13±0.84  p=0.006
Serum EGF level (pg/ml) mean  1.15±0.73   1.96±0.93  p=0.001
Serum TNF_ level (pg/ml) median  0.17±0.27   0.18±0.97  p>0.05
Figure 1. Distribution of neuropathies according to electrophysi-
ological studies in cobalamin-deficient patients
Distribution of neurop athies in patients with cobalamine
deficiency by electrophysiological studies (n=41)
Sensorimotor peripheral neuropathy
n=3
7.32% Symphathetic (sudomotor)
autonomic dysfunction
n=7
17.07%
n=19
46.34%
Parasymphatethic 
(Cardiovagal autonomic
dysfunction)
no
neuropathy
n=12
29.27%patients with Cbl deficiency. However, serum TNF-_ 
levels were not significantly different between Cbl-
deficient patients and healthy controls. After Cbl 
replacement, only serum EGF levels increased sig-
nificantly. Neurological abnormalities were demon-
strated in EPS in 29 of 41 patients (70.73%) and 
among them, autonomic dysfunction was present 
in 26 of 41 Cbl-deficient patients (63.41%). There 
was no association between serum levels of EGF, 
TNF-_, IL-6, and autonomic dysfunction as assessed 
by EPS (p>0.05). In our study group, serum Cbl 
levels were 120 pg/ml in only 22 of 41 patients, so 
not all our patients had severe Cbl deficiency. This 
situation might be considered a limitation of our 
study.
Mean corpuscular volume (MCV) of our patient 
group with Cbl deficiency was 91.85±17.19 fl 
(mean). Generally, severe macrocytosis is expect-
ed in Cbl deficiency anemia. Nevertheless, our 
patient population consisted of not only megalo-
blastic anemia patients due to Cbl deficiency but 
also patients with Cbl deficiency without anemia 
who had neurological symptoms and signs. 
Furthermore, some of the patients had additional 
iron deficiency. Relatively moderate macrocytosis 
in our patients with Cbl deficiency can be explained 
by these factors. 
It has been demonstrated that the Cbl-deficient 
central neuropathy of totally gastrectomized (TGX) 
rats is not caused by the withdrawal of the vitamin 
itself, but reflects a simultaneous increase in the 
production of the neurotoxic cytokine TNF-_ and a 
decrease in the synthesis of the neurotrophic 
growth factor EGF and IL-6 [10-12,14]. In two stud-
ies, cytokine levels were detected in humans with 
Cbl deficiency [15,16]. In the first report by Peracchi 
et al. [15], it was demonstrated that overproduc-
tion of serum TNF-_ and underproduction of 
serum EGF were present in humans with newly 
diagnosed severe Cbl deficiency, as in rats. Later, 
Scalabrino et al. [16] reported higher TNF-_ levels 
and lower EGF levels in the CSF of Cbl-deficient 
patients with neurological manifestations of sub-
acute combined degeneration (SCD). We could 
not demonstrate an increase in serum TNF-_ levels 
in the Cbl-deficient patients or a relationship 
between serum IL-6, TNF-_ and EGF levels and 
autonomic dysfunction. Severity of Cbl deficiency 
and the presence of clinical SCD in the study of 
Peracchi et al. [15] may be the major factor 
explaining the discrepancy between the two stud-
ies. The duration of Cbl deficiency may also be a 
leading factor for the changes in serum neuro-
trophic and neurotoxic cytokine levels. 
Although the most common clinical manifesta-
tions of Cbl deficiency are SCD of the spinal cord 
and peripheral neuropathy, optic atrophy, demen-
tia, and autonomic nervous system dysfunction 
have been reported rarely [1-4]. In the previous 
studies, parameters of heart rate variability in 
patients with Cbl deficiency were found to be sig-
nificantly lower as compared to healthy controls 
[17,18]. Orthostatic hypotension as a function of 
autonomic neuropathy was systematically assessed 
in patients with Cbl deficiency by Beitzke et al. [3]. 
In their study, a significant fall in systolic blood 
pressure directly after head-up tilt, stroke index, 
and cardiac index, and a lack of increase of total 
peripheral resistance index for the duration of tilt in 
patients with Cbl deficiency as compared to healthy 
controls were reported. In patients with Cbl defi-
ciency, gastric emptying by scintigraphy has also 
been studied as a function of the autonomic ner-
vous system. Mean gastric emptying t1/2 in patients 
with Cbl deficiency was reported to be prolonged. 
Although mean gastric emptying t1/2 after Cbl 
replacement therapy was somewhat shorter, a sta-
tistically significant difference persisted after Cbl 
replacement [4].
In conclusion, our present study showed that 
neurotrophic cytokines EGF and IL-6 serum levels 
decreased while neurotoxic cytokine TNF-_ serum 
level did not change in patients with Cbl deficiency 
as compared with healthy controls. Nevertheless, 
we could not find a relation between autonomic 
neuropathy and changes in serum neurotrophic 
and neurotoxic cytokines levels in Cbl-deficient 
patients. Presence of asymptomatic autonomic 
neuropathy seems to be a frequent neurological 
finding in patients with Cbl deficiency. To determine 
the clinical relevance of neurotoxic and neurotroph-
ic cytokine levels, further studies are needed. 
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